Peripheral neuropathy screening

Jump to navigation Jump to search

Peripheral neuropathy Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating peripheral neuropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Peripheral neuropathy screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Peripheral neuropathy screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Peripheral neuropathy screening

CDC on Peripheral neuropathy screening

Peripheral neuropathy screening in the news

Blogs on Peripheral neuropathy screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Peripheral neuropathy screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Annual screening for peripheral neuropathy is recommended every year among patients with diabetes mellitus by: Semmes-Weinstein monofilament examination, Superficial pain sensation testing, vbration testing by the on-off method and vibration testing by the timed method. The reported operating characteristics for each sensory modality can be applied to positive findings on the physical examination of individual patients to predict the likelihood of neuropathy. Semmes-Weinstein monofilament examination is an appropriate, cheap and easy to use tool for identifying patients at risk of having neuropathy in primary care setting in patients with diabetes mellitus. The 1 g monofilament and total Norfolk quality of life diabetic neuropathy are effective, low-cost tools for the early detection of diabetic peripheral neuropathy. The 128 Hz tuning fork and 10 g monofilament may assist diabetic peripheral neuropathy screening as a tandem, but not primary, early diabetic peripheral neuropathy detection screening tools.

Screening

  • The 1 g monofilament and total Norfolk quality of life diabetic neuropathy are effective, low-cost tools for the early detection of diabetic peripheral neuropathy. The 128 Hz tuning fork and 10 g monofilament may assist diabetic peripheral neuropathy screening as a tandem, but not primary, early diabetic peripheral neuropathy detection screening tools.[4]

References

  1. 1.0 1.1 Perkins BA, Olaleye D, Zinman B, Bril V (2001). "Simple screening tests for peripheral neuropathy in the diabetes clinic". Diabetes Care. 24 (2): 250–6. PMID 11213874.
  2. 2.0 2.1 Ogbera AO, Adeleye O, Solagberu B, Azenabor A (2015). "Screening for peripheral neuropathy and peripheral arterial disease in persons with diabetes mellitus in a Nigerian University Teaching Hospital". BMC Res Notes. 8: 533. doi:10.1186/s13104-015-1423-2. PMC 4592746. PMID 26435536.
  3. Al-Geffari M (2012). "Comparison of different screening tests for diagnosis of diabetic peripheral neuropathy in Primary Health Care setting". Int J Health Sci (Qassim). 6 (2): 127–34. PMC 3616942. PMID 23580893.
  4. Brown JJ, Pribesh SL, Baskette KG, Vinik AI, Colberg SR (2017). "A Comparison of Screening Tools for the Early Detection of Peripheral Neuropathy in Adults with and without Type 2 Diabetes". J Diabetes Res. 2017: 1467213. doi:10.1155/2017/1467213. PMC 5698816. PMID 29250555.

Template:WH Template:WS